

## TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

**Leuven (Belgium) – October 11, 2013** – TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by Mr. Steven Verraes (with address at Kastanjedreef 6, 8510 Rollegem, Belgium), who notifies alone, regarding the crossing below the 3% threshold on October 7, 2013 following the transfer of shares, after which Mr. Verraes held 2,529,377 shares (2.00%) (compared to the denominator of 126,288,586 shares).

For further details regarding these notifications, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

**For more information:**

Eduardo Bravo  
Chief Executive Officer  
[eduardo.bravo@tigenix.com](mailto:eduardo.bravo@tigenix.com)

Claudia D'Augusta  
Chief Financial Officer  
[claudia.daugusta@tigenix.com](mailto:claudia.daugusta@tigenix.com)

Hans Herklots  
[hans.herklots@tigenix.com](mailto:hans.herklots@tigenix.com)  
+32 16 39 60 97

**About TiGenix**

*TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit [www.tigenix.com](http://www.tigenix.com).*